Silence Therapeutics PLC (LON:SLN)

Silence Therapeutics PLC (LON:SLN)

Share Price
69.50 p
2.75 (4.12 %)
Market Cap
£49.74 m
Proactive Investors - Run By Investors For Investors

Silence Therapeutics PLC RNS Release

Appointment of Chief Financial Officer

RNS Number : 5591W
Silence Therapeutics PLC
18 April 2019

Silence Therapeutics Appoints Dr. Rob Quinn as Chief Financial Officer


April 18, 2019



LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce the appointment of Rob Quinn as full time Chief Financial Officer, effective immediately.


Dr. Quinn has served as the Interim Chief Financial Officer of Silence since January 2019, having been the Head of Financial Planning and Analysis at the Company for the two years prior to this. He has a wealth of both financial and scientific experience and before joining Silence he held a senior role at GSK, as Area Finance Director for Africa & Developing Countries. Dr. Quinn is a Chartered Accountant and qualified at  Deloitte, including time spent working in corporate finance advisory within the life sciences sector. He also holds a PhD in Biochemistry from the University of Manchester. Dr. Quinn will not be appointed to the Board of Directors.


David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:

"I'm very pleased that Rob will serve as full time Chief Financial Officer and on behalf of the Board I would like to formally welcome him to this role. Rob's scientific and financial skills, alongside his commercial acumen make him an asset to the Silence team. During his time at the Company he has continued to play an important role in building the business, with a keen appreciation for how we will grow in the future".








Silence Therapeutics plc

Dr David Horn Solomon, Chief Executive Officer


Tel:  +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson


Tel:  +44 (0)20 7418 8900

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

[email protected]


Tel: +44 (0) 20 3709 5700


Westwicke Partners

Peter Vozzo

[email protected]


 Tel: +1 (443) 213-0505


About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

Silence Therapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use